Skip to main content
  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

  • Home
  • About this Journal
    • General Statistics
    • Editorial Board
    • Editors
    • Information for Advertisers
    • Author Reprints
    • Commercial Reprints
    • Customer Service and Ordering Information
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • AHA Guidelines and Statements
    • Acknowledgment of Reviewers
    • Clinical Implications
    • Clinical-Pathological Conferences
    • Controversies in Hypertension
    • Editors' Picks
    • Guidelines Debate
    • Meeting Abstracts
    • Recent Advances in Hypertension
    • SPRINT Trial: the Conversation Continues
  • Resources
    • Instructions to Reviewers
    • Instructions for Authors
    • →Article Types
    • → Submission Guidelines
      • Research Guidelines
        • Minimum Information About Microarray Data Experiments (MIAME)
      • Abstract
      • Acknowledgments
      • Clinical Implications (Only by invitation)
      • Conflict(s) of Interest/Disclosure(s) Statement
      • Figure Legends
      • Figures
      • Novelty and Significance: 1) What Is New, 2) What Is Relevant?
      • References
      • Sources of Funding
      • Tables
      • Text
      • Title Page
      • Online/Data Supplement
    • →Tips for Easier Manuscript Submission
    • → General Instructions for Revised Manuscripts
      • Change of Authorship Form
    • → Costs to Authors
    • → Open Access, Repositories, & Author Rights Q&A
    • Permissions to Reprint Figures and Tables
    • Journal Policies
    • Scientific Councils
    • AHA Journals RSS Feeds
    • International Users
    • AHA Newsroom
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
  • Facebook
  • Twitter

  • My alerts
  • Sign In
  • Join

  • Advanced search

Header Publisher Menu

  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

Hypertension

  • My alerts
  • Sign In
  • Join

  • Facebook
  • Twitter
  • Home
  • About this Journal
    • General Statistics
    • Editorial Board
    • Editors
    • Information for Advertisers
    • Author Reprints
    • Commercial Reprints
    • Customer Service and Ordering Information
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • AHA Guidelines and Statements
    • Acknowledgment of Reviewers
    • Clinical Implications
    • Clinical-Pathological Conferences
    • Controversies in Hypertension
    • Editors' Picks
    • Guidelines Debate
    • Meeting Abstracts
    • Recent Advances in Hypertension
    • SPRINT Trial: the Conversation Continues
  • Resources
    • Instructions to Reviewers
    • Instructions for Authors
    • →Article Types
    • → Submission Guidelines
    • →Tips for Easier Manuscript Submission
    • → General Instructions for Revised Manuscripts
    • → Costs to Authors
    • → Open Access, Repositories, & Author Rights Q&A
    • Permissions to Reprint Figures and Tables
    • Journal Policies
    • Scientific Councils
    • AHA Journals RSS Feeds
    • International Users
    • AHA Newsroom
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
Scientific Contributions

β2-Adrenergic Receptor Gene Variation and Hypertension in Subjects With Type 2 Diabetes

Kristina Bengtsson, Marju Orho-Melander, Olle Melander, Ulf Lindblad, Jonas Ranstam, Lennart Råstam, Leif Groop
Download PDF
https://doi.org/10.1161/01.HYP.37.5.1303
Hypertension. 2001;37:1303-1308
Originally published May 1, 2001
Kristina Bengtsson
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marju Orho-Melander
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Olle Melander
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ulf Lindblad
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jonas Ranstam
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lennart Råstam
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Leif Groop
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Info & Metrics
  • eLetters

Jump to

  • Article
    • Abstract
    • Methods
    • Results
    • Discussion
    • Acknowledgments
    • References
  • Figures & Tables
  • Info & Metrics
  • eLetters
Loading

Abstract

Abstract—The aim of this study was to investigate whether polymorphisms in the β2-adrenergic receptor gene (5′LC-Arg19Cys, Arg16Gly, Gln27Glu) are associated with hypertension in patients with or without type 2 diabetes and with the blood pressure levels in normotensive sib pairs. The association study included 291 hypertensive patients without type 2 diabetes, 124 hypertensive patients with type 2 diabetes, and 265 healthy control subjects from Sweden. In addition, normotensive sib pairs that were discordant for the Arg16Gly (72 pairs) and Gln27Glu (40 pairs) polymorphisms were identified in type 2 diabetes families from Finland. Genotyping was performed using polymerase chain reaction–restriction fragment-length polymorphism analysis. Homozygous carriers of the Arg16 allele had a significantly increased odds ratio (OR) for hypertension in patients with type 2 diabetes (OR 2.14; 95% confidence interval [CI], 1.05 to 4.33), particularly among lean (body mass index<27 kg/m2) patients (OR 3.47; 95% CI, 1.06 to 11.33). The Gln27 allele showed a weaker association to hypertension (OR 1.55; 95% CI, 1.00 to 2.41) and was found to be in linkage disequilibrium with the Cys19 allele of the 5′LC-Arg19Cys polymorphism. In the paired-sibling analysis, siblings with at least 1 copy of the Arg16 allele had higher systolic blood pressure (P=0.049), and nondiabetic siblings had a higher body mass index (P=0.026) than siblings homozygous for the Gly16 allele. These results indicate that the Arg16 allele of the β2-adrenergic receptor gene confers an increased risk for hypertension in subjects with type 2 diabetes and is associated with higher blood pressure levels and higher body mass index in sib pairs who are discordant for the polymorphism.

  • genetics
  • hypertension, genetic
  • blood pressure
  • diabetes
  • receptors, adrenergic, beta
  • sibling

The β2-adrenergic receptors (B2AR) are G-protein coupled receptors, which are widely distributed in the body, and they mediate vasodilatation, bronchial dilatation, and lipolysis.1 2 Three common polymorphisms in the B2AR gene on chromosome 5q31 to 32 have been reported: Arg16Gly, Gln27Glu, and 5′LC-Arg19Cys.3 4 Several studies have investigated the role of these polymorphisms in asthma,5 obesity,6 7 and hypertension.8 9 10 Whereas the findings in asthma have been consistent,11 the relationship between these polymorphisms and hypertension and obesity is unclear.

The Gly16 allele of the Arg16Gly polymorphism has been ascribed a greater degree of agonist-induced downregulation of the receptor in transfected fibroblasts and human bronchial smooth muscle12 but also with a 5-fold increased sensitivity to catecholamine-induced lipolysis in human adipocytes.6 The Gly16 allele has been associated with hypertension in African Caribbeans8 and with elevated blood pressure and reduced vasodilatation after infusion of salbutamol in normotensive Austrian males.13 However, the Arg16 allele has been associated with elevated blood pressure in the offspring of Norwegians9 and Germans.10 Although the Gln27Glu polymorphism has been associated with obesity,6 7 14 type 2 diabetes, and hypertriglyceridemia,15 these findings have not been replicated in other studies.16 17 The Gln27Glu polymorphism is in linkage disequilibrium with the 5′LC-Arg19Cys polymorphism in the 5′-leader cistron (5′LC).4 The 5′LC codes for a polypeptide that seems to affect the expression of the receptor18 and could therefore influence the susceptibility to hypertension,4 obesity, and type 2 diabetes.19

The aim of this study was to investigate the role of the Arg16Gly, Gln27Glu, and 5′LC-Arg19Cys polymorphisms in the B2AR gene in hypertension and type 2 diabetes in a case-control association study and in genotype-discordant sibling pairs.

Methods

For the case-control association study, we enrolled 291 unrelated hypertensive patients without type 2 diabetes and with age at onset of ≤60 years and 265 unrelated healthy control subjects without medication, personal history of hypertension, first-degree family history of hypertension, or type 2 diabetes from southern Sweden.20 The subjects identified in the Skaraborg Hypertension and Diabetes Project consisted of 2 cohorts. One cohort included 1149 patients with hypertension and/or diabetes and the other cohort included an age-stratified, random sample (1400 invited, 1109 participating) from the population 40 years of age and older. Hypertensive patients and normotensive spouses from 250 families were recruited from healthcare centers in the Scania region. In addition, 124 unrelated hypertensive patients with type 2 diabetes were ascertained from the Skaraborg Hypertension and Diabetes project.21 Three subjects were excluded because of genotyping failure and misclassification. Hypertension was defined as 3 consecutive blood pressure measurements ≥160 mm Hg (systolic blood pressure) and/or ≥90 mm Hg (diastolic blood pressure) or ongoing antihypertensive treatment. The control subjects had systolic and diastolic blood pressures ≤150 mm Hg and ≤80 mm Hg, respectively. The diagnosis of type 2 diabetes was based on criteria from the World Health Organization.22 The participants were categorized as follows:1 all hypertensives are patients with hypertension, regardless of whether they had type 2 diabetes or not (n=415);2 hypertensives without type 2 diabetes (n=291);3 hypertensives with type 2 diabetes (n=124); and4 healthy controls (n=265) (Table 1⇓).

View this table:
  • View inline
  • View popup
Table 1.

Clinical Characteristics of Individuals in the Case-Control Association Study and in the Genotype-Discordant Sib-Pair Study

For the genotype-discordant sib pair study, 494 normotensive siblings were ascertained from 118 families with type 2 diabetes in Botnia, Finland,23 and they were genotyped for the B2AR gene Arg16Gly and Gln27Glu polymorphisms to identify genotype discordant pairs. In total, we identified 72 sib pairs in which 1 of the siblings was homozygous for the Gly16 allele and the other sibling carried either 1 or 2 Arg16 alleles. Similarly, we identified 40 sib pairs in which 1 of the siblings was homozygous for the Glu27 allele whereas the other sibling had 1 or 2 Gln27 alleles. The 72 sib pairs who were discordant for Arg16Gly polymorphism originated from 46 sibships that comprised 118 individuals, and the 40 sib pairs who were discordant for the Gln27Glu polymorphism originated from 26 sibships and included 64 individuals (Table 1⇑). The ethics committees of the Gothenburg and Lund University approved the study. Informed consent was obtained from all the participants.

Blood pressure was measured with a sphygmomanometer after 5 minutes of rest in the supine position in the Swedish subjects and twice within 10 minutes after 15 minutes of rest in the sitting position in the Finnish subjects, the values given are the averages of the 2 measurements. Body weight and height were measured and body mass index (BMI) was calculated. BMI ≥27 kg/m2 was considered as overweight. Total genomic DNA was extracted from the whole blood by standard methods.24

The Arg16Gly and Gln27Glu polymorphisms were genotyped by polymerase chain reaction and restriction fragment-length polymorphism methods. The Arg16Gly polymorphism was amplified in a genomic 203-bp fragment using primers β2 to 16-MM-F (5′-CGCCTTCTTGCTGGCACGCAAT) and β2 to 16/27-R (5′-CCAGTGAAGTGATGAAGTAGTT), of which the former contains a nucleotide mismatch (underlined) to create a BsrDl recognition site in case of the Gly16 allele. The Gln27Glu polymorphism was amplified in a genomic 169-bp fragment with primers β2 to 27-MM-F (5′-CCGGACCACGACGTCACCCAG) and β2 to 16/27-R, of which the former contains a nucleotide mismatch (underlined) to create a BstNl recognition site in case of the Glu27 allele. The primers were designed according to the published B2AR cDNA sequence.1 PCR reactions were performed with 50 ng of genomic DNA in a total volume of 20 μL containing 10 pmol of each primer, 4 nmol dNTPs, 0.5 U Taq polymerase (Pharmacia) in 1x (NH4)2SO4-buffer (16 mmol/L [NH4]2SO4; 67 mmol/L Tris, pH 8.8; 0.01% Tween), with 3% formamide, and 1.5 mmol/L MgCl2. PCR conditions were as follows: initial denaturation at 94°C for 5 minutes, followed by 30 cycles of denaturation (94°C for 30 seconds), annealing (60°C for 30 seconds), and extension (72°C for 30 seconds), with the final extension at 72°C for 10 minutes. The PCR products were digested for 2 hours at 60°C using the buffers recommended by the manufacturer. The product containing the Arg16Gly polymorphism was digested with 1 U of BsrDl (New England Biolabs), which produced 2 fragments of 22 and 181 bps in case of the Gly16 allele, leaving the Arg16 allele uncut. The product containing the Gln27Glu polymorphism was digested with 1 U of BstNl (New England Biolabs), which resulted in 2 fragments of 95 and 75 bps in case of Gln27 allele and 3 fragments of 20, 58, and 95 bps in case of the Glu27 allele. The fragments were separated on 4.5% multipurpose agarose gel (Appligene) with ethidium bromide and visualized under ultraviolet light.

A genomic 172-bp fragment containing the 5′LC-Arg19Cys polymorphism was PCR amplified with a forward primer 5′-GAATGAGGCTTCCAGGCGTCC and a reverse primer 5′- GTCGTGGTCCGGCGCATGGC. PCR reactions were performed with 50 ng of genomic DNA in a total volume of 20 μL containing 10 pmol of each primer, 2 nmol dNTPs, 0.5 U Taq polymerase (Amersham Pharmacia) in a PCR buffer recommended by the manufacturer (Pharmacia) with 1.5% formamid. PCR conditions were as follows: initial denaturation at 95°C for 5 minutes, followed by 30 cycles of denaturation (94°C for 30 seconds), annealing (65°C for 30 seconds), and extension (72°C for 30 seconds), with the final extension at 72°C for 10 minutes. The PCR products were digested in a total volume of 30 μL for 3 hours at 37°C with 1 U of MspA1I restriction endonuclease (Promega) in a buffer recommended by the manufacturer. The MspA1I cuts the 5′LC-Arg19 allele to fragments of 144 and 54 bps, whereas the 5′LC-Cys19 allele remains intact. The fragments were separated on 4.5% multipurpose agarose gel (Appligene) with ethidium bromide and visualized under ultraviolet light.

Statistical Methods

Results are presented as mean±SD. Differences between group means were tested by ANCOVA. Association between genotypes and hypertension was analyzed by logistic regression and expressed as odds ratio (OR) with 95% confidence interval (CI) and with the Gly16Gly and Glu27Glu genotypes as reference. Data from the genotype-discordant sib pairs were analyzed using a modified permutation test for paired replicates.25 26 The 2-tailed probability value was estimated using a large (107) random sample from all possible permutations. If the observed sum of differences entered into the 5% region of rejection, the difference between pairs was considered statistically significant. For sib pairs discordant for the Arg16Gly polymorphism, the differences in phenotypic variables were computed as the values in the sibling with the Arg16Arg or Gly16Arg genotype minus the value in the sibling with the Gly16Gly genotype. For sib pairs discordant for the Gln27Glu polymorphism, the differences were computed as the values in the sibling with the Gln27Gln or Gln27Glu genotype minus the value in the sibling with the Glu27Glu genotype. Analyses, except the permutation tests, were performed using BMDP Statistical Software version 1.12 and an SPSS statistical program (SPSS/PC+ for the IBM-PC/XT/AT, 1986). All statistical tests were 2-sided, and P<0.05 was considered statistically significant.

Results

In the Swedish population, the genotype frequencies for the Arg16Gly polymorphism in the B2AR gene were 13.4% for Arg16Arg, 45.6% for Arg16Gly, and 41.0% for the Gly16Gly genotype, and the genotype frequencies for the Gln27Glu polymorphism were 30.1% for Gln27Gln, 48.5% for Gln27Glu, and 21.3% for the Glu27Glu genotype. This is in accordance with the genotype frequencies reported in other European populations.4 The observed genotype frequencies in the different study groups were in Hardy-Weinberg equilibrium. The codon 16 and 27 polymorphisms were in linkage disequilibrium in the Swedish population: 100% of the Arg16-carrying chromosomes had Gln at position 27, whereas 28% of the Gly16-carrying chromosomes had Gln and 72% had Glu in position 27. The 5′LC-Arg19Cys polymorphism was in tight linkage disequilibrium with the Gln27Glu polymorphism; the Cys19 allele was associated with the Gln27 allele in all but 1 (n=1112) chromosome.

There was a significant increase in the OR (OR 2.14; 95% CI, 1.05 to 4.33, P=0.035) for hypertension in the Arg16Arg genotype carriers with type 2 diabetes (Table 2⇓). Similarly, there was an increase in the OR for hypertension in the Gln27Gln genotype carriers (OR 1.55; 95% CI, 1.00 to 2.41, P=0.050). Neither the Arg16 nor the Gln27 allele conferred an increased risk for hypertension in subjects without type 2 diabetes. The carriers of the different genotypes showed no statistically significant difference between the serum creatinine values and the occurrence of proteinuria. The Arg16Arg genotype was associated with hypertension, especially in the nonobese (BMI<27 kg/m2) subgroup of patients with hypertension and type 2 diabetes (OR 3.47; 95% CI, 1.06 to 11.33, P=0.040).

View this table:
  • View inline
  • View popup
Table 2.

OR for All HT and for HT With and Without Type 2 Diabetes for the Arg16Gly and Gln27Glu Polymorphisms in B2AR Gene

Among the sib pairs discordant for the Arg16Gly polymorphism, those siblings carrying 1 or 2 Arg16 alleles had higher systolic blood pressure compared with individuals homozygous for the Gly16 allele (P=0.049, Table 3⇓). Among the nondiabetic pairs (n=54), siblings with 1 or 2 Arg16 alleles had a higher BMI than siblings homozygous for Gly16 (P=0.026). This was due to the male siblings (11 pairs), 25.9 kg/m2 versus 24.4 kg/m2 (P=0.018). Figure 1⇓ shows the difference in blood pressure and BMI of the individuals in the sib pair combinations used in the permutation test. There was a significant difference in systolic blood pressure between the siblings and in BMI in nondiabetic siblings homozygous for the Gly16 allele and carriers of 1 or more Arg16 alleles.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Clinical characteristics of the sib pairs discordant for the Arg16Gly polymorphism of the β2-adrenergic receptor gene. *P=0.049; **P=0.026.

View this table:
  • View inline
  • View popup
Table 3.

Differences in Clinical Characteristics of Siblings Discordant for the Arg16Gly and Gln27Glu Polymorphisms Analyzed by the Permutation Test

There were no significant differences in blood pressure levels or BMI between siblings discordant for the Gln27Glu polymorphism.

Discussion

The key finding of the present study was an increased risk for hypertension in type 2 diabetic carriers of the Arg16 and Gln27 alleles of the B2AR gene. This increased risk was not due to differences in nephropathy between the carriers. We also found that normotensive siblings from families with type 2 diabetes carrying 1 or 2 Arg16 alleles had a higher systolic blood pressure and a higher BMI compared with siblings homozygous for Gly16 allele. Because the B2AR regulates blood pressure as well as glucose and fat metabolism, we tested the B2AR polymorphisms for association with hypertension as well as diabetes and obesity. Some caution in interpretation of the data is warranted because we performed more than 1 test. The observed association between hypertension and the Arg16 allele is in accordance with a previous report in Scandinavians.9 In addition, a recent study in German twins showed that the Arg16 allele was associated with higher systolic blood pressure levels.10 On the other hand, Gratze et al found that young normotensive white male subjects homozygous for the Gly16 allele had higher blood pressure and decreased peripheral vasodilatation in response to salbutamol infusion.13 In addition, an association between the Gly16 allele and hypertension has been reported in African Caribbeans.8 Salt-sensitive individuals show a greater downregulation of the B2AR in response to high-salt intake.27 Black Africans are known to be more salt sensitive than whites,28 which has been proposed to explain the association between hypertension and the Gly16 allele in African Caribbeans.8

There are several other polymorphisms in the vicinity of the Arg16Gly polymorphism, such as the 5′LC-Arg19Cys, Gln27Glu, and Thr164Ile. Unfortunately, previous studies have not taken linkage disequilibrium between these polymorphisms into account. In vitro the 5′LC-Cys19 allele has been associated with an increase in B2AR gene expression, the Glu27 allele has been associated with a resistance to downregulation, the Ile164 allele has been associated with an impaired Gs-protein coupling,12 and the Arg16 allele has been associated with decreased receptor density on the surface of cultured human fibroblasts.29 Liggett and coworkers reported that the Gly16 allele is associated with increased agonist-induced downregulation of the B2AR in Chinese hamster fibroblasts and that the effect of the Gly16 allele dominates when combined with the Glu27 allele.12 Interestingly, the Glu27 allele has otherwise been shown to be resistant to agonist-induced downregulation.30

In this study we found that the haplotype LC-Cys19-Arg16-Gln27 was associated with increased risk for hypertension in the case-control association study and with elevated systolic blood pressure and higher BMI in genotype-discordant sib pairs. The allele frequencies of the polymorphisms in the B2AR gene differ between different populations.31 The findings that the Arg16 allele is associated with hypertension and higher blood pressure levels in Scandinavians, whereas the Gly16 allele is associated with hypertension in other populations,8 13 may suggest that it is not the Gly16Arg polymorphism per se but rather some polymorphism in linkage disequilibrium with the Gly16Arg polymorphism that is responsible for the association.

Because of the well-established link between hypertension and obesity, we also analyzed BMI in relation to codon 16 and 27 genotypes. We observed that the Arg16 allele was associated with a higher BMI in the sib-pair study. This is not surprising because of the strong linkage disequilibrium between the Gly16Arg and Gln27Glu polymorphisms. Several studies have shown that the Glu27 allele is associated with obesity.6 15 19 However, other studies have found the Gln27 allele to be associated with obesity in males.7 32 Our data are in accordance with a predominant role of the B2AR gene in promoting obesity in males. The difference in BMI in sib pairs was restricted to male subjects with the Arg16 allele.

In conclusion, the Arg16 and Gln27 alleles of the B2AR gene confer an increased risk for hypertension in nonobese patients with type 2 diabetes. This association was replicated in a sib-pair analysis showing that siblings with 1 or 2 Arg16 alleles had higher systolic blood pressure levels and BMI than siblings homozygous for the Gly16 allele.

Acknowledgments

This research was funded by Swedish Heart Lung Foundation; the Swedish Medical Research Council; National Public Health Institute; Skaraborg Institute; Skaraborg County Council, West Region County; the Region Skane; the Faculty of Medicine, Lund University; the Påhlsson Foundation, Malmö University Hospital; the Ernhold Lundström and the Crafoord Foundations; and the NEPI Foundation (The Swedish Network of Pharmacoepidemiology). The Botnia Study was supported by grants from the Sigrid Juselius Foundation, Academy of Finland, Swedish Medical Research Council, and European Economic Community Paradigm (BM44-CT95-0662). We are most grateful to Ann Carlsson, Agneta Edman, and Lena Rosberg for excellent technical assistance.

  • Received May 25, 2000.
  • Revision received June 21, 2000.
  • Accepted October 30, 2000.

References

  1. ↵
    Kobilka BK, Dixon RAF, Frielle T, Dohlman HG, Bolanowski MA, Sigal IS, Yang-Feng TL, Francke U, Caron MG, Lefkowitz RJ. cDNA for the human β2-adrenergic receptor: a protein with multiple membrane-spanning domains and encoded by a gene whose chromosomal location is shared with that of the receptor for platelet-derived growth factor. Proc Natl Acad Sci. 1987;84:46–50.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    Swales JD, ed. Textbook of Hypertension. Oxford, England: Blackwell Scientific Publisher;1994.
  3. ↵
    Reihsaus E, Innis M, MacIntyre N, Liggett SB. Mutations in the gene encoding for the β2-adrenergic receptor in normal and asthmatic subjects. Am J Respir Cell Mol Biol. 1993;8:334–339.
  4. ↵
    McGraw DW, Forbes SL, Kramer LA, Liggett SB. Polymorphisms of the 5′leader cistron of the human β2-adrenergic receptor regulate receptor expression. J Clin Invest. 1998;102:1927–1932.
    OpenUrlCrossRefPubMed
  5. ↵
    Green SA, Turki J, Hall IP, Liggett SB. Implications of genetic variability of human β2-adrenergic receptor structure. Pulm Pharmacol. 1995;8:1–10.
    OpenUrlCrossRefPubMed
  6. ↵
    Large V, Hellström L, Reynisdottir S, Lönnquist F, Eriksson P, Lannfeldt L, Arner P. Human Beta-2 adrenoceptor gene polymorphisms are highly frequent in obesity and associate with altered adipocyte Beta-2 adrenoceptor function. J Clin Invest. 1997;100:3005–3013.
    OpenUrlCrossRefPubMed
  7. ↵
    Hellström L, Large V, Reynisdottir S, Wahrenberg H, Arner P. The different effects of a Gln27Glu β2-adrenoceptor gene polymorphism on obesity in males and in females. J Intern Med. 1999;245:253–259.
    OpenUrlCrossRefPubMed
  8. ↵
    Kotanko P, Binder A, Tasker J, DeFreitas P, Kamdar S, Clark AJL, Skrabal F, Caulfield M. Essential hypertension in African Caribbeans associates with a variant of the β2-adrenoceptor. Hypertension. 1997;30:773–776.
    OpenUrlAbstract/FREE Full Text
  9. ↵
    Timmermann B, Mo R, Luft FC, Gerdts E, Busjahn A, Omvik P, Li G-H, Schuster H, Wienker TF, Hoehe MR, Lund-Johansen P. β2-Adrenoceptor genetic variation is associated with genetic predisposition to essential hypertension: The Bergen Blood Pressure Study. Kidney Int. 1998;53:1455–1460.
    OpenUrlCrossRefPubMed
  10. ↵
    Busjahn A, Li G-H, Faulhaber H-D, Rosenthal M, Becker A, Jeschke E, Schuster H, Timmermann B, Hoehe MR, Luft FC. β2-Adrenergic receptor gene variations, blood pressure, and heart size in normal twins. Hypertension. 2000;35:555–560.
    OpenUrlAbstract/FREE Full Text
  11. ↵
    Dewar JC, Wheatley AP, Venn A, Morrison JFJ, Britton J, Hall IP. β2-Adrenoceptor polymorphisms are in linkage disequilibrium, but are not associated with asthma in an adult population. Clin Exp Allergy. 1998;28:442–448.
    OpenUrlCrossRefPubMed
  12. ↵
    Liggett S. Molecular and genetic basis of β2-adrenergic receptor function. J Allergy Clin Immunol. 1999;104:S42–S46.
    OpenUrlCrossRefPubMed
  13. ↵
    Gratze G, Fortin J, Labugger R, Binder A, Kotanko P, Timmermann B, Luft FC, Hoehe MR, Skrabal F. β2-Adrenergic receptor variants affect resting blood pressure and agonist-induced vasodilation in young adult Caucasians. Hypertension. 1999;33:1425–1430.
    OpenUrlAbstract/FREE Full Text
  14. ↵
    Mori Y, Kim-Motoyama H, Ito Y, Katakura T, Yasuda K, Ishiyama-Shigemoto S, Yamada K, Akanuma Y, Ohashi Y, Kimura S, Yazaki Y, Kadowaki T. The Gln27Glu β2-adrenergic receptor variant is associated with obesity due to subcutaneous fat accumulation in Japanese men. Biochem Biophys Res Commun. 1999;258:138–140.
    OpenUrlCrossRefPubMed
  15. ↵
    Ishiyama-Shigemoto S, Yamada K, Yuan X, Ichikawa F, Nonaka K. Association of polymorphisms in the β2-adrenergic receptor gene with obesity, hypertriglyceridaemia, and diabetes mellitus. Diabetologia. 1999;42:98–101.
    OpenUrlCrossRefPubMed
  16. ↵
    Kortner B, Wolf A, Wendt D, Beisiegel U, Evans D. Lack of association between a human β-2 adrenoceptor gene polymorphism (gln27glu) and morbid obesity. Int J Obesity. 1999;23:1099–1100.
    OpenUrlCrossRefPubMed
  17. ↵
    Echwald SM, Sörensen TIA, Tybjaerg-Hansen A, Andersen T, Pedersen O. Gln27Glu variant of the human β2-adrenoceptor gene is not associated with early-onset obesity in Danish men. Diabetes. 1998;47:1657–1658.
    OpenUrlCrossRefPubMed
  18. ↵
    Parola AL, Kobilka BK. The peptide product of a 5′leader cistron in the β2 adrenergic receptor mRNA inhibits receptor synthesis. J Biol Chem. 1994;269:4497–4505.
    OpenUrlAbstract/FREE Full Text
  19. ↵
    Yamada K, Ishiyama-Shigemoto S, Ichikawa F, Yuan X, Koyanagi A, Koyama W, Nonaka K. Polymorphism in the 5′-leader cistron of the β2-adrenergic receptor gene associated with obesity and type 2 diabetes. J Clin Endocrinol Metab. 1999;84:1754–1757.
    OpenUrlCrossRefPubMed
  20. ↵
    Melander O, Bengtsson K, Orho-Melander M, Lindblad U, Forsblom C, Råstam L, Groop L, Hulthén UL. Role of the Gly460Trp polymorphism of the α-adducin gene in primary hypertension in Scandinavians. J Hum Hypertens. 2000;14:43–46.
    OpenUrlCrossRefPubMed
  21. ↵
    Bög-Hansen E, Lindblad U, Bengtsson K, Ranstam J, Melander A, Råstam L. Risk factor clustering in patients with hypertension and NIDDM: The Skaraborg Hypertension Project. J Int Med. 1998;243:223–232.
    OpenUrlPubMed
  22. ↵
    WHO Study Group. Diabetes Mellitus. Geneva, Switzerland: World Health Organization; 1985.
  23. ↵
    Groop L, Forsblom C, Lethovirta M, Tuomi T, Karanko S, Nissén M, Ehrnström B-O, Forsén B, Isomaa B, Snickars B, Taskinen M-R. Metabolic consequences of a family history of NIDDM (The Botnia Study) evidence for sex-specific parental effects. Diabetes. 1996;45:1585–1593.
    OpenUrlAbstract/FREE Full Text
  24. ↵
    Sambrooks J, Fritsch EF, Maniatis T. Molecular cloning: A Laboratory Manual. 2nd ed. New York: Cold Spring Harbour; 1989.
  25. ↵
    Sidney S, Castellan NJ. The permutation test for paired replicates. In: Editions M-HI, ed. Nonparametric Statistics for the Behavioral Sciences: The Case of One Sample, Two Measures or Paired Replicates. 2nd ed. Singapore: McGraw-Hill Book Co; 1988:95–101.
  26. ↵
    Orho-Melander M, Almgren P, Kanninen T, Forsblom C, Groop LC. A paired-sibling analysis of the Xba1 polymorphism in the muscle glycogen synthase gene. Diabetologia. 1999;42:1138–1145.
    OpenUrlCrossRefPubMed
  27. ↵
    Kotanko P, Höglinger O, Skrabal F. β2-Adrenoceptor density in fibroblast culture correlates with human NaCl sensitivity. Am J Physiol. 1992;263:C623–C627.
    OpenUrlAbstract/FREE Full Text
  28. ↵
    Luft FC, Grim CE, Higgins JT, Weinberger MH. Differences in response to sodium administration in normotensive white and black subjects. J Lab Clin Med. 1977;90:555–562.
    OpenUrlPubMed
  29. ↵
    Kotanko P, Höglinger O, Binder A, Skrabal F. Further evidence for reduced beta2-adrenoceptor expression and modification of its density at a level beyond gene expression. Diabetologia. 1995;38:126–128.
    OpenUrlPubMed
  30. ↵
    Liggett S. Functional properties of human β2-adrenergic receptor polymorphisms. News Physiol Sci. 1995;10:265–273.
    OpenUrlAbstract/FREE Full Text
  31. ↵
    Aynacioglu AS, Cascorbi I, Gungör K, Özkur M, Bekir N, Roots I, Brockmöller J. Population frequency, mutation linkage and analytical methodology for the Arg16Gly, Gln27Glu, and Thr164Ile polymorphisms in the β2-adrenergic receptor among Turks. J Clin Pharmacol. 1999;48:761–764.
  32. ↵
    Meirhaeghe A, Helbecque N, Cottel D, Amoyel P. β2-adrenoceptor gene polymorphism, body weight, and physical activity. Lancet. 1999;353:896.
    OpenUrlCrossRefPubMed
View Abstract
Back to top
Previous ArticleNext Article

This Issue

Hypertension
May 2001, Volume 37, Issue 5
  • Table of Contents
Previous ArticleNext Article

Jump to

  • Article
    • Abstract
    • Methods
    • Results
    • Discussion
    • Acknowledgments
    • References
  • Figures & Tables
  • Info & Metrics
  • eLetters

Article Tools

  • Print
  • Citation Tools
    β2-Adrenergic Receptor Gene Variation and Hypertension in Subjects With Type 2 Diabetes
    Kristina Bengtsson, Marju Orho-Melander, Olle Melander, Ulf Lindblad, Jonas Ranstam, Lennart Råstam and Leif Groop
    Hypertension. 2001;37:1303-1308, originally published May 1, 2001
    https://doi.org/10.1161/01.HYP.37.5.1303

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
  •  Download Powerpoint
  • Article Alerts
    Log in to Email Alerts with your email address.
  • Save to my folders

Share this Article

  • Email

    Thank you for your interest in spreading the word on Hypertension.

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    β2-Adrenergic Receptor Gene Variation and Hypertension in Subjects With Type 2 Diabetes
    (Your Name) has sent you a message from Hypertension
    (Your Name) thought you would like to see the Hypertension web site.
  • Share on Social Media
    β2-Adrenergic Receptor Gene Variation and Hypertension in Subjects With Type 2 Diabetes
    Kristina Bengtsson, Marju Orho-Melander, Olle Melander, Ulf Lindblad, Jonas Ranstam, Lennart Råstam and Leif Groop
    Hypertension. 2001;37:1303-1308, originally published May 1, 2001
    https://doi.org/10.1161/01.HYP.37.5.1303
    del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Related Articles

Cited By...

Subjects

  • Genetics
    • Genetics
  • Cardiology
    • Etiology
      • Hypertension
        • Hypertension
  • Epidemiology, Lifestyle, and Prevention
    • Diabetes, Type 2
    • Epidemiology

Hypertension

  • About Hypertension
  • Instructions for Authors
  • AHA CME
  • Guidelines and Statements
  • Permissions
  • Journal Policies
  • Email Alerts
  • Open Access Information
  • AHA Journals RSS
  • AHA Newsroom

Editorial Office Address:
7272 Greenville Ave.
Dallas, TX 75231
email: hypertension@heart.org

Information for:
  • Advertisers
  • Subscribers
  • Subscriber Help
  • Institutions / Librarians
  • Institutional Subscriptions FAQ
  • International Users
American Heart Association Learn and Live
National Center
7272 Greenville Ave.
Dallas, TX 75231

Customer Service

  • 1-800-AHA-USA-1
  • 1-800-242-8721
  • Local Info
  • Contact Us

About Us

Our mission is to build healthier lives, free of cardiovascular diseases and stroke. That single purpose drives all we do. The need for our work is beyond question. Find Out More about the American Heart Association

  • Careers
  • SHOP
  • Latest Heart and Stroke News
  • AHA/ASA Media Newsroom

Our Sites

  • American Heart Association
  • American Stroke Association
  • For Professionals
  • More Sites

Take Action

  • Advocate
  • Donate
  • Planned Giving
  • Volunteer

Online Communities

  • AFib Support
  • Garden Community
  • Patient Support Network
  • Professional Online Network

Follow Us:

  • Follow Circulation on Twitter
  • Visit Circulation on Facebook
  • Follow Circulation on Google Plus
  • Follow Circulation on Instagram
  • Follow Circulation on Pinterest
  • Follow Circulation on YouTube
  • Rss Feeds
  • Privacy Policy
  • Copyright
  • Ethics Policy
  • Conflict of Interest Policy
  • Linking Policy
  • Diversity
  • Careers

©2018 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. The American Heart Association is a qualified 501(c)(3) tax-exempt organization.
*Red Dress™ DHHS, Go Red™ AHA; National Wear Red Day ® is a registered trademark.

  • PUTTING PATIENTS FIRST National Health Council Standards of Excellence Certification Program
  • BBB Accredited Charity
  • Comodo Secured